Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

04. Oktober 2020 18:39 ET | Quelle: Sorrento Therapeutics, Inc.

Sorrento to Host a R&D Day to Showcase COVID-19 Product Pipeline

SAN DIEGO, Oct. 04, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced it will host a R&D Day conference call and simultaneous webcast on October...
16. September 2020 21:30 ET | Quelle: Sorrento Therapeutics, Inc.

Sorrento Receives US FDA Clearance to Proceed With Phase 1 Clinical Trial of STI-1499 (COVI-GUARD) Neutralizing Antibody in COVID-19 Positive Patients

Phase 1 clinical trial for STI-1499 (COVI-GUARD™) in hospitalized COVID-19 patients has received FDA notice that it may proceed with patient enrollment.The initial trial is expected to enroll rapidly...
19. August 2020 09:00 ET | Quelle: Sorrento Therapeutics, Inc.

Sorrento Announces FDA IND Filing Today for COVI-GUARD Neutralizing and High Potency Antibody Against SARS-CoV-2

IND filing today for STI-1499 (COVI-GUARD™) for hospitalized COVID-19 patients.The initial trial is expected to be followed by pivotal trials with a goal of potentially receiving an EUA (Emergency Use...